LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Tumor Markers in Blood Underpins Future Bowel Cancer Screening

By LabMedica International staff writers
Posted on 09 Dec 2014
Print article
Image: Proposed mechanism of genetic material from tumor entering into circulation (Photo courtesy of University of Utah).
Image: Proposed mechanism of genetic material from tumor entering into circulation (Photo courtesy of University of Utah).
The positivity from a two-gene DNA blood test increases with the depth of cancer invasion, tumor size, stage and presence of metastases in bowel cancer patients.

The two-genes are known as IKAROS Family Zinc Finger 1 (IKZF1) and branched chain amino-acid transaminase 1, cytosolic (BCAT1) and they become methylated during the development of bowel cancer and the ability to detect the methylated form serves as a biomarker for this disease.

Scientists at Flinders Center for Innovation in Cancer (Bedford Park, SA, Australia) worked with the biotechnology company Clinical Genomics (North Ryde, NSW, Australia) who created the test. They studied a population of 1,777 people scheduled for colonoscopy— 111 were identified with bowel cancer. The blood test revealed that cancer stage, vascular invasion and metastasis significantly correlated with the presence of the two methylated DNA markers in blood.

The IKZF1 methylation patterns can change during progression of bowel cancer, thus complicating detection of early stage cancers. Using a modified blood test designed to detect a range of various methylation patterns in the IKZF1 DNA target improved the 2-gene blood test sensitivity for 24 early stage cancers (Stage I+II) from 25 to 46% leading to an overall improved sensitivity for 33 individuals for any cancer from 64% to 70%, with 92% specificity.

Susanne Pedersen, PhD, Chief Scientific Officer at Clinical Genomics, said, “Understanding the process by which DNA fragments from tumors enter into circulation in blood is crucial to building confidence around new screening approaches for the future. Pathology providers and medical practitioners are likely to be more accepting of these new screening approaches as we come to understand more about the biology and mechanisms that leads to the presence of these tumor biomarkers in blood.” The study was presented at the Australian Gastroenterology Week (AGW) conference held October 22-24, 2014, in Gold Coast (QLD, Australia).

Related Links:
Flinders Center for Innovation in Cancer
Clinical Genomics


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more